The Value Of Tokenizing Clinical Development Data

When working to accelerate therapies and devices for patients during clinical development, accessing and linking real-world data (RWD) can pose some of the greatest challenges. While RWD enables teams to focus on the needs of patients and reduce unnecessary spending, there are existing challenges that must be overcome to realize the benefit.

To realize the full potential of RWD in clinical development, it is important to understand that using RWD does not need to be an “either/or” decision. RWD should be assessed through the lens of “fit for this purpose” versus “fit for any purpose.” The clinical development strategy should be developed including RWD in structured and meaningful ways, and it should be tied to clear and measurable use cases.

In terms of deriving value from real-world data, the most prominent use cases in the industry don’t currently require tokenization of the clinical research data to deliver the value. However, given these challenges and the influx of data, innovative methods for bringing disparate data sources together, including tokenization, provide an effective way to address the challenges. Explore how teams can experience a return on investment from the tokenization of clinical trial data.